Stockreport

Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF - PIPE-307 demonstrated an acceptable safety and tolerability profile- PIPE-307 treatment did not result in a significant change in binocular 2.5% low contrast letter ac [Read more]